Royalty Pharma plc Class A Ordinary Shares RPRX
$69.45
+0.99%
at last close
Market Cap$30.92 billion
P/E Ratio—
Div Yield1.35%
Volume3.42M
52-Week Range
$35.23$69.77
Analyst Ratings
- Consensus
- Buy — 5 Buy · 0 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $66.40 (-4.4% downside)
Key Stats
- Today's Range
- $67.73 – $69.63
- 50-Day Range
- $55.13 – $69.77
- 52-Week Range
- $35.23 – $69.77
- Volume
- 3.42 million shs
- Average Volume
- 3.36 million shs
- Market Cap
- $30.92 billion
- P/E Ratio
- —
- Dividend Yield
- 1.35%
Dividend
- Dividend Yield
- 1.35%
- Annual Dividend
- $0.94
- Payout Ratio
- —
- Ex-Dividend Date
- 2026-11-13
Short Interest
- Short Interest
- 0.34%
- Days to Cover
- 2.12
About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Related Stocks
Compare head-to-head: RPRX vs LLY·RPRX vs JNJ·RPRX vs ABBV·RPRX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.